Lutetium-DOTATATE

Theranostics

It is a peptide receptor radionuclide therapy (PRRT) for treatment of somatostatin receptor-positive gastro-entero-pancreatic neuroendocrine tumors. The treatment course is composed of up to 4 intra-venous doses of 150-200 mCi (once every 2 months) according to the response.

  • It is injected in the blood stream where it identifies and attaches to the receptors on the cancer cells using the DOTATATE amino acid.
  • 177Lutetium emits β-rays that have a very short range in soft tissues (average of 0.23 mm) leading to cell damage of affected cells and low risk to neighboring cells.
  • Low or intermediate grade NET (ki-67<20%).
  • High somatostatin receptor expression based on 68Gallium-DOTATATE PET/CT.
  • Adequate bone marrow, renal and hepatic functions.
  • Avoid administering long acting octreotide for 4 weeks prior to Lutetium dose and 24 hours in case of short acting octreotide.
  • 177Lu-DOTATATE had a 79% reduction in risk of progression.
  • Estimated progression free survival of 40 months, compared with only 8.4 months for high-dose (60mg) octreotide therapy.

RESERVE AN APPOINTMENT OR CONSULT A DOCTOR?

Call 19773 Now or Fill The Contact Form